超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

MicuRx 盟科醫藥  
MicuRx 致力于發現和開發治療由耐藥菌引起感染的新型抗生素。該公司將其美國研發團隊的豐富經驗與中國高品質、高經濟效益的藥物研發優勢相結合，逐漸建立起一個治療各類耐藥革蘭氏陽性和陰性菌新藥的平臺。該公司在美國加州硅谷和中國張江設有研發實驗室。MicuRx 在首輪風險融資中從 Morningside Group 和 Devon Park Bioventures  募集了1200萬美元。

 
盟科醫藥技術（上海）有限公司成立于2007年7月,致力于開發擁有自主知識產權的新一代抗菌藥物，以解決日益嚴重的、由于耐藥菌引起的感染，并在未來實現其工業生產和商業化。
經過三年多的高效運轉，公司自主研發的第一個候選1.1類新藥MRX-I，其前期研究得到了國家“十一五重大新藥創制”的一定支持，現已完成了前期藥學，毒理和生產工藝的研究，于2009年在中國申報臨床試驗（IND），并已取得中國食品藥品監督管理局進行臨床試驗的批文，已經進入一期人體臨床試驗。該1.1類新藥有望于2015年前后在中、美同時上市，預期全球市場可達十億美元。
   


MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.

Infections due to multi-drug resistant bacteria have become a major threat to public health. In particular, methicillin-resistant Staphylococcus aureus (MRSA) has quickly spread from the hospital setting into the community and vancomycin-resistant enterococci (VRE) now represents at least 30% of all hospital enterococci infections. Importantly, bacteria continue to evolve and new strains of bacteria are resistant to even the newest antibiotics.

Using its proprietary drug discovery platform, MicuRx has generated a broad pipeline of antimicrobial agents to treat Gram-positive, Gram-negative and fungal infections. MicuRx's lead drug candidate is MRX-I, a next-generation oxazolidinone antibiotic with a superior therapeutic window projected to offer significant clinical differences over existing drugs. MicuRx filed its first Investigational New Drug (IND) application in China and received "Special Review" status from the State Food and Drug Administration.

In addition to its internal pipeline, MicuRx and Pfizer have entered a collaboration agreement to discover and develop new therapeutic agents to treat drug-resistant tuberculosis. All collaboration research will be conducted at the ZhangJiang High-Tech Park in Shanghai, China.